A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Baricitinib (Primary) ; Triamcinolone
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 14 Mar 2017 Status changed from active, no longer recruiting to completed.
- 12 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Mar 2017.